The post XRP Remains in Tight Consolidation Around $1.40 as Traders Eye Next Move Towards $1.80 appeared on BitcoinEthereumNews.com. Key Insights: The asset staysThe post XRP Remains in Tight Consolidation Around $1.40 as Traders Eye Next Move Towards $1.80 appeared on BitcoinEthereumNews.com. Key Insights: The asset stays

XRP Remains in Tight Consolidation Around $1.40 as Traders Eye Next Move Towards $1.80

For feedback or concerns regarding this content, please contact us at crypto.news@mexc.com

Key Insights:

  • The asset stays in a tight consolidation range, hinting at potential breakout toward $1.80 resistance.
  • Whale activity sees 130 million XRP redistributed, influencing future price movements.
  • XRP ETFs experience a $4.19M inflow, reflecting growing institutional interest.
XRP Remains in Tight Consolidation Around $1.40 as Traders Eye Next Move Towards $1.80

XRP has remained relatively stable, trading around the $1.40 mark after several months of downtrend. Currently, the digital asset is moving inside a narrow consolidation range, signaling that a potential shift could be on the horizon. As the market continues to observe the cryptocurrency, traders are closely monitoring its price action, especially after recent activity.

Current Market Conditions for XRP

The price for the asset has shown signs of stability, hovering at $1.40. This range has sparked increased interest from both traders and investors, who are looking for clues about the next potential price move. 

According to BitGuru, after months of downtrend, the toke price is now moving inside a tight consolidation range around $1.40. This phase often comes before a bigger move. If the price breaks through resistance levels, it could potentially lead to a recovery toward the $1.80 zone.

XRP Inside a Tight Consolidation Range | Source: X

In the past 24 hours, the token has experienced a slight decline of 1.86%. The current 24-hour trading volume stands at $2.45 billion. Despite the price decline, market observers are still cautious, as a larger move could be approaching.

Whale Activity and ETF Inflows Fuel XRP’s Movement

Meanwhile, whale movements are making waves in the asset market. Over 130 million XRP have been redistributed by large holders in the past 24 hours, indicating that major players are still active within the market. This redistribution could influence the coin’s future price action, with whales potentially pushing the price in either direction.

In addition, the asset ETFs have seen a notable inflow of 3.08 million XRP, valued at $4.19 million, over the last 24 hours. This indicates a growing interest from institutional investors.

The influx of capital into XRP ETFs could be a positive sign for the asset’s price in the near term. Traders and analysts are keeping an eye on these developments, as they may indicate whether the token is poised for further upside.

DISCLAIMER: The information on this website is provided as general market commentary and does not constitute investment advice. We encourage you to do your own research before investing.

Source: https://coincu.com/analysis/xrp-remains-in-tight-consolidation-around-1-40-as-traders-eye-next-move-towards-1-80/

Market Opportunity
Ucan fix life in1day Logo
Ucan fix life in1day Price(1)
$0.0004868
$0.0004868$0.0004868
-6.65%
USD
Ucan fix life in1day (1) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact crypto.news@mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Key Takeaways Vitalik Buterin wants Ethereum apps built to survive without developers, corporate servers, or trusted third parties Two major […] The post Vitalik
Share
Coindoo2026/03/07 15:49
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26
Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

The post Short-term profit-taking pushes Bitcoin back below key $70K level – What next? appeared on BitcoinEthereumNews.com. Bitcoin [BTC] rallied as high as $74
Share
BitcoinEthereumNews2026/03/07 16:09